MONTREAL, March 14 /CNW Telbec/ - Nexia Biotechnologies Inc. (TSX: NXB) today announced completion of the sale of substantially all of its operations and assets related to Protexia(R) (recombinant human butyrylcholinesterase) to a wholly-owned subsidiary of PharmAthene, Inc. ("PharmAthene"), a privately held biotechnology company focused on the development of biodefense therapeutics, based in Annapolis, Maryland.
